Sulfatinib (b)( HMPL-012 | Surufatinib | HMPL012 )

Catalog No. M11232 CAS No. 1308672-74-3

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Sulfatinib (b)
Note

Research use only, not for human use.
Brief Description

Sulfatinib (HMPL-012) is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1/2/3, FGFR1, CSF1R with IC50 of 2/24/1 nM, 15 nM, 4 nM, respectively.
Description

Sulfatinib (HMPL-012) is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1/2/3, FGFR1, CSF1R with IC50 of 2/24/1 nM, 15 nM, 4 nM, respectively; also potently inhibits TrkB and FLT-3 with IC50 of 41 and 67 nM, shows little to no activity against other 278 other kinases (IC50>150 nM); targets tumor angiogenesis and immune modulation, exhibits an acceptable safety profile and encouraging antitumor activity in clinical investigations.Brain Cancer Phase 3 Clinical.
In Vitro

——
In Vivo

——
Synonyms

HMPL-012 | Surufatinib | HMPL012
Pathway

Angiogenesis
Target

VEGFR
Recptor

VEGFR
Research Area

Cancer
Indication

Brain Cancer

CAS Number

1308672-74-3
Formula Weight

480.5825
Molecular Formula

C24H28N6O3S
Purity

>98% (HPLC)
Solubility

DMSO: ≥ 30 mg/mL
SMILES

CC1=CC2=C(N1)C=CC(OC3=NC(NC4=CC(CS(NCCN(C)C)(=O)=O)=CC=C4)=NC=C3)=C2
Chemical Name

Benzenemethanesulfonamide, N-[2-(dimethylamino)ethyl]-3-[[4-[(2-methyl-1H-indol-5-yl)oxy]-2-pyrimidinyl]amino]-

1. Xu JM, et al. Oncotarget. 2017 Jun 27;8(26):42076-42086.

Calculator

molnova catalog